rethinkTHC Search
Menu
Study breakdown

Baseline Inflammation Levels Influenced Whether Cannabis Helped Anxiety and Sleep

ObservationalPreliminary evidence
The takeaway

In people with anxiety, baseline inflammatory status shaped how different cannabis chemovars affected mood and sleep, with CBD-dominant products showing the most consistent improvements.

People with anxiety exploring cannabis as a treatment option and researchers studying personalized cannabis medicine.

CBD chemovars produced more consistent improvements regardless of inflammatory state

What the researchers found

While cannabis use did not change cytokine concentrations over four weeks, baseline inflammation moderated outcomes. People with higher baseline inflammation responded differently to different cannabis chemovars. CBD-dominant products produced more consistent improvements in negative affect and sleep quality, while THC-associated improvements varied depending on the person's inflammatory state.

Why it matters

This is among the first studies to show that a person's inflammatory profile may predict whether cannabis will help their anxiety and sleep. It suggests a possible biological reason why cannabis works for some people with anxiety but not others.

The numbers in context

147 participants across three cannabis chemovars, 24 controls. No group-dependent changes in cytokines (p=0.12). Baseline inflammation moderated DASS-21 outcomes (p<0.05) and sleep quality (p=0.04). CBD chemovars showed more consistent improvements.

How the study worked

Participants with mild or greater anxiety (n=147) were assigned to one of three cannabis chemovars (THC+CBD, THC-only, CBD-only) for 4 weeks of ad libitum use and compared to an anxiety control group (n=24). Depression, anxiety, stress (DASS-21), sleep quality (PSQI), and plasma cytokines were measured at baseline and week 4.

What this study cannot tell us

Non-randomized assignment to chemovars. Ad libitum use means dosing varied. Small control group (24). Four-week follow-up may be too short for stable effects. Cannot determine optimal THC:CBD ratios from this design.

How to read the evidence

Preliminary: non-randomized design with small control group and ad libitum dosing, though novel biomarker approach.

When this study was published

2025 study.

The bigger picture

Personalized medicine approaches to cannabis are in their infancy. This study suggests that measuring inflammation could eventually help predict who will benefit from cannabis for anxiety and which chemovar to recommend.

Questions still open

  • Could a simple blood test for inflammation help guide cannabis chemovar selection? What specific inflammatory markers are most predictive? Would longer-term use show different results?

Common questions

Did cannabis reduce inflammation?
No. Cytokine levels did not change significantly over 4 weeks in any group. However, baseline inflammation levels influenced how well cannabis worked for mood and sleep.
Which type of cannabis worked best for anxiety?
CBD-dominant products produced the most consistent improvements, while THC effects varied depending on the person's baseline inflammatory state.

Read the original research

Inflammatory state moderates response to cannabis on negative affect and sleep quality in individuals with anxiety.

Frontiers in behavioral neuroscience, 19, 1549311

Citation

Lisano, Jonathon K; Skrzynski, Carillon J; Giordano, Gregory; Bryan, Angela D; Bidwell, L Cinnamon. (2025). Inflammatory state moderates response to cannabis on negative affect and sleep quality in individuals with anxiety.. Frontiers in behavioral neuroscience, 19, 1549311. https://doi.org/10.3389/fnbeh.2025.1549311

Explore the wider topic